Entrada Therapeutics (TRDA) Earnings Date, Estimates & Call Transcripts → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free TRDA Stock Alerts $12.36 -0.07 (-0.56%) (As of 04/25/2024 ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Earnings SummaryUpcoming Earnings DateMay. 8EstimatedActual EPS (Mar. 13) -$0.29 Missed By -$0.22 Consensus EPS (Mar. 13) -$0.07 Get Entrada Therapeutics Earnings AlertsEnter your email address below to receive the latest news and earnings results for TRDA and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueTRDA Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.TRDA Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> Entrada Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20242($0.73)($0.40)($0.57)Q2 20242($0.61)($0.42)($0.52)Q3 20242($0.64)($0.48)($0.56)Q4 20242($0.67)($0.52)($0.60)FY 20248($2.65)($1.82)($2.24)Q1 20251($0.69)($0.69)($0.69)Q2 20251($0.72)($0.72)($0.72)Q3 20251($0.76)($0.76)($0.76)Q4 20251($0.66)($0.66)($0.66)FY 20254($2.83)($2.83)($2.83)TRDA Earnings Date and InformationEntrada Therapeutics last issued its earnings results on March 13th, 2024. The reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.07) by $0.22. The firm had revenue of $41.85 million for the quarter, compared to analyst estimates of $27.82 million. Entrada Therapeutics has generated ($0.26) earnings per share over the last year (($0.26) diluted earnings per share). Earnings for Entrada Therapeutics are expected to decrease in the coming year, from ($1.54) to ($2.78) per share. Entrada Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, May 8th, 2024 based off prior year's report dates.Read More Entrada Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 5/8/2024Estimated)------- 3/13/2024Q4 2023($0.07)($0.29)($0.22)($0.29)$27.82 million$41.85 million11/7/2023Q3 2023($0.55)$1.02+$1.57$1.02$16.31 million$43.74 million8/8/2023Q2 2023($0.43)($0.78)($0.35)($0.78)$19.56 million$18.17 million5/10/2023Q1 2023($0.77)($0.21)+$0.56($0.21)-$25.26 million3/6/2023Q4 2022($0.83)($0.79)+$0.04($0.79)--11/7/2022Q3 2022-($0.80)($0.80)($0.80)-- Get the Latest News and Ratings for TRDA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Entrada Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/11/2022Q2 2022-($0.74)($0.74)($0.74)--5/12/2022Q1 2022-($0.69)($0.69)($0.69)--3/15/2022Q4 2021-($0.89)($0.89)($0.89)--12/8/2021Q3 2021($0.87)($9.78)($8.91)($9.78)-- Entrada Therapeutics Earnings - Frequently Asked Questions When is Entrada Therapeutics's earnings date? Entrada Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, May 8th, 2024 based off last year's report dates. Learn more on TRDA's earnings history. Did Entrada Therapeutics beat their earnings estimates last quarter? In the previous quarter, Entrada Therapeutics (NASDAQ:TRDA) missed the analysts' consensus estimate of ($0.07) by $0.22 with a reported earnings per share (EPS) of ($0.29). Learn more on analysts' earnings estimate vs. TRDA's actual earnings. How much revenue does Entrada Therapeutics generate each year? Entrada Therapeutics (NASDAQ:TRDA) has a recorded annual revenue of $129.01 million. How much profit does Entrada Therapeutics generate each year? Entrada Therapeutics (NASDAQ:TRDA) has a recorded net income of -$6.68 million. TRDA has generated -$0.26 earnings per share over the last four quarters. What is Entrada Therapeutics's EPS forecast for next year? Entrada Therapeutics's earnings are expected to decrease from ($1.54) per share to ($2.78) per share in the next year. More Earnings Resources from MarketBeat Related Companies: Biomea Fusion Earnings Date Harrow Health Earnings Date Lexicon Pharmaceuticals Earnings Date Heron Therapeutics Earnings Date PepGen Earnings Date Neurogene Earnings Date Mersana Therapeutics Earnings Date Revance Therapeutics Earnings Date Avid Bioservices Earnings Date Fulcrum Therapeutics Earnings Date Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: GE Aerospace is Ready for Liftoff After Strong EarningsTaiwan Semiconductor Earnings: AI Dominance and Future OutlookCSX Co.: The Railroad Powering Ahead with an Earnings Beat What's Driving Tesla Lower Ahead of its Earnings?Blackrock vs. State Street: Earnings in a Volatile MarketWhat to Expect From the Q1 Earnings Reporting SeasonLululemon Stock Implodes Post Earnings, Guidance Muted This page (NASDAQ:TRDA) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsJim Cramer’s “The Biggest Drug Ever”Behind the MarketsThe only accurate crypto trading system I know …Weiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entrada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
